EU CHMP Opinions And MAA Updates

Recommendations by the European Medicines Agency’s human medicines committee (the CHMP) on the authorization of new medicines in the EU and updates on marketing authorization changes recommended by the CHMP. Updated monthly.

The CHMP meets once a month to review marketing applications as part of the EU’s centralized marketing procedure. CHMP opinions are sent to the European Commission, which makes a final, legally binding decision, usually within 67 days.

Click on any column header to sort by that topic. The search box can be used to filter results.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".